Executive Summary
China Medical System Holdings Limited and its subsidiaries is an integrated and profitable pharmaceutical group focusing on research and development, manufacturing, distributing and marketing of prescription drugs, pharmaceutical products and medical equipment primarily in China.
Company History
The Group was established in May 1995. On 28 December 2006, China Medical System Holdings Limited was incorporated, becoming the current holding company of the Group.
Current Events
Business Model
Products and Services
Sales and marketing is one of the most important core competences of the Group. The Group has a sales and marketing force in 26 provinces and major cities in China, consisting of over 500 full time staff, over 70 per cent. of which have professional backgrounds in medicine or pharmacy. The Group's portfolio has five products with sole distribution rights in the PRC, three in-house developed products and a range of medical equipments. Their principal products are marketed by their sales and marketing professionals and sold by approximately 300 distributors to more than 3,000 hospitals in China. Through their sales and marketing professionals' efforts, the Group's revenue has grown by a compound average rate of 20 per cent. in the past three years, with gross profit and net profit margins at above 50 per cent. and 20 per cent. respectively.
Research and Development
The concerted effort of establishing the R&D platform and developing the Group's own patented products forms another most important core competence of the Group. Since the start of its R&D activities over 6 years ago, CMS Group has obtained 37 drug patents in the PRC and 2 patents overseas while it is in the process of applying for 21 drug patents in the PRC and 92 overseas. There are 8 projects under development in their pipeline. Among these are patented drugs for the treatment of primary liver carcinoma and non-small cell lung cancer, which have completed Phase IIb and Phase I clinical trials respectively in the PRC.
CMS will continue specializing in the medicine area especially in prescription pharmaceuticals, and maintain their competitive advantage through their integrated chain of R&D, manufacturing, sales and marketing, thereby maximizing their opportunity for profit.
R&D Pipeline
The Group has eight products in the pipeline under development; they are mainly derived from peptides and microbiological stheirces. In relation to the research areas, CMS is primarily engaged in development of small molecular polypeptide, the…
